Journal
GENOME MEDICINE
Volume 12, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13073-020-0721-z
Keywords
Immunotherapy; Immune evasion; Data integration; Web platform
Categories
Funding
- Cancer Immunologic Data Commons grant of the National Cancer Institute (NCI) [1U24CA224316-01]
- Pathway to Independence Award grant of NCI [1K99CA218900-01]
- Partnership for Accelerating Cancer Therapies Grant from the Foundation for the National Institute of Health
Ask authors/readers for more resources
Despite growing numbers of immune checkpoint blockade (ICB) trials with available omics data, it remains challenging to evaluate the robustness of ICB response and immune evasion mechanisms comprehensively. To address these challenges, we integrated large-scale omics data and biomarkers on published ICB trials, non-immunotherapy tumor profiles, and CRISPR screens on a web platform TIDE (). We processed the omics data for over 33K samples in 188 tumor cohorts from public databases, 998 tumors from 12 ICB clinical studies, and eight CRISPR screens that identified gene modulators of the anticancer immune response. Integrating these data on the TIDE web platform with three interactive analysis modules, we demonstrate the utility of public data reuse in hypothesis generation, biomarker optimization, and patient stratification.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available